Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505521 | 1.00 | KDM4E (0.51) | KDM4EPKMGPR119STSJAK2 | |
| SCHEMBL19063869 | 0.90 | NAMPT (0.48) | KDM4EPKMGPR119STSJAK2 | |
| SCHEMBL21725308 | 0.90 | NAMPT (0.48) | KDM4EPKMGPR119STSJAK2 | |
| SCHEMBL19063866 | 0.90 | NAMPT (0.48) | KDM4EPKMGPR119STSJAK2 | |
| SCHEMBL19063865 | 0.90 | NAMPT (0.48) | KDM4EPKMGPR119STSJAK2 | |
| SCHEMBL6776034 | 0.88 | GPR119 (0.48) | KDM4EPKMGPR119STSJAK2 | |
| SCHEMBL6776029 | 0.88 | GPR119 (0.48) | KDM4EPKMGPR119STSJAK2 | |
| SCHEMBL25691702 | 0.86 | MEN1 (0.49) | KDM4EPKMGPR119STSJAK2 | |
| SCHEMBL7985552 | 0.85 | KDM4E (0.69) | KDM4EPKMGPR119STSKEAP1 | |
| SCHEMBL4490032 | 0.85 | CXCR4 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334304-B2 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-18 | — | — | US | disclosed |
| US-8334304-B2 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-18 | — | — | US | disclosed |
| EP-1641783-B1 | AMINOSULFONYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2305254-A1 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists for the treatment of gatrointestinal conditions | Janssen Pharmaceutica NV (BE) | 2011-04-06 | — | — | EP | disclosed |
| US-7732464-B2 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7732464-B2 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-20100087483-A1 | Aminosulfonyl Substituted 4-(Aminomethyl)-Piperidine Benzamides As 5HT 4-Antagonists | BOSMANS JEAN-PAUL RENE MARIE ANDRE | 2010-04-08 | — | — | US | disclosed |
| US-20100087483-A1 | Aminosulfonyl Substituted 4-(Aminomethyl)-Piperidine Benzamides As 5HT 4-Antagonists | BOSMANS JEAN-PAUL RENE MARIE ANDRE | 2010-04-08 | — | — | US | disclosed |
| US-7652040-B2 | gastrointestinal disorders hypermotility, irritable bowel syndrome, constipation or diarrhea | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| US-7638535-B2 | (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-7635706-B2 | 1-butyl-3-hydroxy4-piperidinyl)methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylate and chemical intermediates; treating hypermotility, irritable bowel syndrome (IBS) constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-22 | — | — | US | disclosed |
| US-7635706-B2 | 1-butyl-3-hydroxy4-piperidinyl)methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylate and chemical intermediates; treating hypermotility, irritable bowel syndrome (IBS) constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-22 | — | — | US | disclosed |
| US-7498347-B2 | Hydroxycarbonylphenyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4 antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-03 | — | — | US | disclosed |
| US-7498347-B2 | Hydroxycarbonylphenyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4 antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-03 | — | — | US | disclosed |
| US-20070197600-A1 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197600-A1 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-23 | — | — | US | disclosed |
| US-20070032486-A1 | 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032486-A1 | 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20060281753-A1 | 4-(Aminomethyl)-piperidine benzamides as 5ht4 - antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060142339-A1 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht 4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142339-A1 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht 4-antagonists | HTR4, HTR2B, HTR2C | KDM4E 199/4885PKM 1187/4885GPR119 180/4885 |
| US-20070032486-A1 | 5Ht4-antagonistic 4-(aminomethyl)-piperidine benzamides | HTR4, HTR2B, TPH2 | KDM4E 666/4885PKM 1526/4885GPR119 118/4885 |
| US-20070197600-A1 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | HTR4, HTR2B, HTR5A | KDM4E 446/4885PKM 998/4885GPR119 126/4885 |
| US-20100087483-A1 | Aminosulfonyl Substituted 4-(Aminomethyl)-Piperidine Benzamides As 5HT 4-Antagonists | HTR4, HTR2B, HTR2C | KDM4E 199/4885PKM 1187/4885GPR119 180/4885 |
| US-20060281753-A1 | 4-(Aminomethyl)-piperidine benzamides as 5ht4 - antagonists | HTR4, HTR2B, HTR5A | KDM4E 348/4885PKM 884/4885GPR119 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.